Who we are

Autolus applies extensive programming capabilities to develop advanced autologous T cell therapies that have the potential to deliver life-changing benefits to cancer patients and is building a fully integrated, next-generation CAR T company

About us


The company’s lead therapeutic candidate, obe-cel, is a potentially transformational treatment for adult Acute Lymphoblastic Leukemia. Obe-cel is an autologous CD19 CAR T cell therapy with a unique CD19 CAR. The CAR is designed to have a “fast-off” kinetic which mimics physiological T cell receptor interactions. Clinical trials of obe-cel have demonstrated that this enhanced kinetic profile results in increased T cell persistence leading to high levels of durable remissions and remarkably low levels of cytokine release syndrome and other immunotoxicities. Obe-cel is currently being evaluated in the potentially pivotal FELIX study in adult ALL and in phase 1 studies for other B-NHL indications. Obe-cel phase 2 pivotal FELIX clinical trial met its primary endpoint at an interim analysis in 2022 with additional data expected in mid-2023.

Find out more

Our Obe-cel Abstracts and Publications

See all
December 12 2022

Dual Antigen Targeting with Co-Transduced CD19/22 CAR T Cells May Prevent Antigen-Negative Relapse after CAR T Cell Therapy for Relapsed/Refractory ALL (AUTO1/22)

December 11 2022

Safety, Efficiency and Long-Term Follow-up of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia (B-ALL) and Other B-Cell Malignancies

American Society of Hematology Annual Meeting
December 13 2021

Safety and Efficacy of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)

Information for patients

Clinical trials are required to gain regulatory approval for new medicines to advance patient care.

Learn more about our CAR T cell therapy clinical trials

Life at Autolus

Whilst working at Autolus you will enjoy a flexible, diverse and dynamic working environment which actively promotes creativity, leadership and teamwork – together we are ONE Autolus.

Careers at Autolus


Autolus is building a fully-integrated, next generation CAR T company. It is committed to the development and commercialization of obe-cel in r/r Adult ALL and is progressing opportunities for obe-cel in additional indications alongside its preclinical and clinical pipeline for hematological malignancies and solid tumors.

View investor information